non-Hodgkin lymphoma

(redirected from Non-Hodgkins lymphoma)
Also found in: Dictionary, Encyclopedia, Wikipedia.

non-Hodg·kin lym·pho·ma (NHL),

a lymphoma other than Hodgkin disease, classified by Rappaport into a nodular or diffuse tumor pattern and by cell type; a working or international formulation separates such lymphomas into low-, intermediate-, and high-grade malignancy and into cytologic subtypes reflecting follicular center cell or other origin.

non-Hodgkin lymphoma

(nŏn′hŏj′kĭn) or

non-Hodgkin's lymphoma

(-kĭnz)
n.
Any of a large group of lymphomas that can be slow-growing or fast-growing, involve malignancies of either B cells or T cells, and are typically distinguished from Hodgkin lymphoma by the absence of Reed-Sternberg cells. Symptoms include enlarged lymph nodes, fever, night sweats, and weight loss.

non-Hodg·kin lym·pho·ma

(non-hoj'kin lim-fō'mă)
A lymphoma other than Hodgkin disease, classified by Rappaport into a nodular or diffuse tumor pattern and by cell type; a working or international formulation separates such lymphomas into low, intermediate, and high grade malignancy and into cytologic subtypes reflecting follicular center cell or other origin.
Enlarge picture
NON-HODGKIN LYMPHOMA: Bizarre-appearing lymphocytes revealing active mitosis (orig. mag. ×1000)

non-Hodgkin lymphoma

Abbreviation: NHL
Any of a group of malignant tumors of B or T lymphocytes. In 2008, the American Cancer Society estimated that about 66,100 Americans would be newly diagnosed with the disease. See: illustration; Hodgkin disease

Symptoms

Painless lymphadenopathy in two thirds of patients is the most frequent presenting symptom. Others have fever, night sweats, and loss of 10% or more of body weight in the 6 months before presenting with symptoms of infiltration into nonlymphoid tissue. Additional involvement is in peripheral areas such as epitrochlear nodes, the tonsillar area, and bone marrow. NHL is 50% more frequent in occurrence in men than in women of similar age. In most cases the cause of NHL is unknown, but patients who have received immunosuppressive agents have an over 100 times greater chance of developing NHL, probably because the immunosuppressive agents activate tumor viruses.

Treatment

Specific therapy depends on the type, grade, and stage of the lymphoma. Combination chemotherapies, bone marrow transplantation, radiation therapy, and photochemotherapy may be given, depending on the specific diagnosis.

See also: lymphoma

Hodgkin,

Thomas, English physician, 1798-1866.
Hodgkin disease - malignant neoplasm of lymphoid cells of uncertain origin, associated with inflammatory infiltration of lymphocytes and eosinophilic leukocytes and fibrosis. Synonym(s): lymphadenoma
Hodgkin-Key murmur - a musical diastolic murmur.
Hodgkin sarcoma
non-Hodgkin lymphoma - a lymphoma other than Hodgkin disease.

non-Hodg·kin lym·pho·ma

(non-hoj'kin lim-fō'mă)
A lymphoma other than Hodgkin disease, classified nodular or diffuse tumor pattern and cell type.
References in periodicals archive ?
Levy said his new approach to non-Hodgkins lymphoma is based on a similar immunotherapy that Dr.
The disproportionate rise in non-Hodgkins Lymphoma (NHL) incidence over the last 40 years remains largely unexplained.
The emerging non-Hodgkins lymphoma therapeutics market generated more that $1 billion USD in revenues in 2000.
Anderson Cancer Center (UTMDACC) in Houston, says "the early results indicate that Onco TCS has promising activity and if this continues with the complete study, Onco TCS has the potential to become an important component in the first line of treatment of certain kinds of non-Hodgkins lymphoma (NHL).
Oncolym(R), the Company's most advanced drug development candidate, is an investigational radiolabeled murine monoclonal antibody being studied in a Phase II/III trial for the treatment of intermediate- and high-grade relapsed or refractory B-cell non-Hodgkins lymphoma.
NASDAQ:CLTR) today presented overall clinical trial results from four separate investigational clinical trials of Bexxar (iodine I 131 tositumomab), the company's lead cancer therapy for the treatment of non-Hodgkins lymphoma (NHL).
Patients are presently being treated in two separate clinical trials; the Phase II/III clinical trial for the treatment of advanced B-cell non-Hodgkins lymphoma with Oncolym(TM) and the Phase I clinical trial for the treatment of malignant glioma (brain cancer) with TNT.
The company's most advanced product candidate is Bexxar (previously referred to as the B-1 Therapy) for the treatment of non-Hodgkins lymphoma.